All articles by Refna Tharayil

Zai Lab and Innoviva get Chinese approval for Xacduro in HABP/VABP

The approval was based on the positive results from Phase 3 ATTACK trial in which Xacduro proved its statistical non-inferiority to colistin regarding the primary endpoint of 28-day all-cause mortality